Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is a promising company with a positive outlook due to recent regulatory approvals and potential breakthrough treatments for obesity and type 2 diabetes. Their lead product candidate, Revita, has shown promising results in weight loss and is set to enter Phase 1/2 trials. The company's streamlined regulatory pathway and potential De Novo reclassification could further accelerate Revita's development and commercialization, adding value to the company and its stock. Additionally, Revita's ability to maintain weight loss and potential to replace chronic drug therapy make it a promising option for the treatment of metabolic diseases.

Bears say

Fractyl Health is currently facing challenges due to its Revita and Rejuva candidates being in the clinical stage and the lack of significant changes in levels of HbA1c in its patients. Moreover, the company's REMAIN-1 pivotal readout in 4Q26 is a binary event with high stakes, as it will determine the potential approval of Revita as a first-in-class procedural therapy for weight maintenance. While the company's projected visual representations of the two endpoints and positive view on the trial success may suggest a potential turnaround in the future, the current risks and uncertainties make us skeptical about the company's financial outlook.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.